Large-scale manufacture and characterization of a lentiviral vector produced for clinical Ex vivo gene therapy application

Human Gene Therapy

Volumn 22, Issue 3, 2011, Pages 343-356

  Merten, Otto Wilhelm ^a   Charrier, Sabine ^a,b   Laroudie, Nicolas ^a   Fauchille, Sylvain ^a   Dugué, Céline ^a   Jenny, Christine ^a   Audit, Muriel ^a   Zanta Boussif, Maria Antonietta ^a   Chautard, Hélène ^a   Radrizzani, Marina ^c   Vallanti, Giuliana ^c   Naldini, Luigi ^d   Noguiez Hellin, Patricia ^a   Galy, Anne ^a,b  

^a GÉNÉTHON   (France)

^b UNIVERSITÉ D EVRY VAL D ESSONNE   (France)

^c 4MolMed ^*  (Italy)

^d SAN RAFFAELE SCIENTIFIC INSTITUTE   (Italy)

Author keywords

[No Author keywords available]

Indexed keywords

CD34 ANTIGEN; DNA; E1A PROTEIN; GLYCOPROTEIN; LENTIVIRUS VECTOR; SIMIAN VIRUS 40 LARGE T ANTIGEN; UNCLASSIFIED DRUG; VESICULAR STOMATITIS VIRUS GLYCOPROTEIN; VIRUS LARGE T ANTIGEN;

ARTICLE; B LYMPHOCYTE; CONTROLLED STUDY; DNA SEQUENCE; EX VIVO STUDY; GENE INSERTION; GENE SEQUENCE; GENE THERAPY; GOOD MANUFACTURING PRACTICE; HUMAN; HUMAN CELL; HUMAN IMMUNODEFICIENCY VIRUS 1; NONHUMAN; PILOT STUDY; TRANSIENT TRANSFECTION; WISKOTT ALDRICH SYNDROME;

CELL CULTURE TECHNIQUES; CELL LINE; DRUG CONTAMINATION; GENE EXPRESSION REGULATION; GENE ORDER; GENE THERAPY; GENETIC VECTORS; HEK293 CELLS; HEMATOPOIETIC STEM CELLS; HUMANS; INDUSTRIAL MICROBIOLOGY; LENTIVIRUS; PLASMIDS; PROVIRUSES; QUALITY CONTROL; TRANSDUCTION, GENETIC; TRANSGENES; WISKOTT-ALDRICH SYNDROME;

HUMAN IMMUNODEFICIENCY VIRUS 1; SIMIAN VIRUS 40; VESICULAR STOMATITIS VIRUS;

EID: 79952688973     PISSN: 10430342     EISSN: None     Source Type: Journal    
DOI: 10.1089/hum.2010.060     Document Type: Article

References (52)

1. Aiuti, A., Slavin, S., Aker, M., et al. (2002). Correction of ADA-SCID by stem cell gene therapy combined with non-myeloablative conditioning. Science 296, 2410-2413. (Pubitemid 34734219)
2. Ansorge, S., Lanthier, S., Transfiguracion, J., et al. (2009). Development of a scalable process for high-yield lentiviral vector production by transient transfection of HEK293 suspension cultures. J. Gene Med. 11, 868-876.
3. Baekelandt, V., Eggermont, K., Michiels, M., et al. (2003). Optimized lentiviral vector production and purification procedure prevents immune response after transduction of mouse brain. Gene Ther. 10, 1933-1940. (Pubitemid 37337069)
4. Biffi, A., De Palma, M., Quattrini, A., et al. (2004). Correction of metachromatic leukodystrophy in the mouse model by transplantation of genetically modified hematopoietic stem cells. J. Clin. Invest. 113, 1118-1129. (Pubitemid 38544097)
5. Burns, J.C., Friedmann, T., Driever, W., et al. (1993). Vesicular stomatitis virus G glycoprotein pseudotyped retroviral vectors: Concentration to very high titer and efficient gene transfer into mammalian and nonmammalian cells. Proc. Natl. Acad. Sci. U.S.A. 90, 8033-8037. (Pubitemid 23260849)
6. Cartier, N., Hacein-Bey-Abina, S., Bartholomae, C.C., et al. (2009). Hematopoietic stem cell gene therapy with a lentiviral vector in X-linked adrenoleukodystrophy. Science 326, 818-823.
7. Cavazzana-Calvo, M., Payen, E., Negre, O., et al. (2010). Transfusion independence and HMGA2 activation after gene therapy of human b-thalassaemia. Nature 467, 318-322.
8. Charrier, S., Stockholm, D., Seye, K., et al. (2005). A lentiviral vector encoding the human Wiskott-Aldrich syndrome protein corrects immune and cytoskeletal defects in WASP knockout mice. Gene Ther. 12, 597-606. (Pubitemid 40468107)
9. Charrier, S., Dupre, L., Scaramuzza, S., et al. (2007). Lentiviral vectors targeting WASp expression to hematopoietic cells, efficiently transduce and correct cells from WAS patients. Gene Ther. 14, 415-428.
10. Denard, J., Rundwasser, S., Laroudie, N., et al. (2009). Quantitative proteomic analysis of lentiviral vectors using 2-DE. Proteomics 9, 3666-3676.
11. Devitt, G., Thomas, M., Klibanov, A.M., et al. (2007). Optimized protocol for the large scale production of HIV pseudovirions by transient transfection of HEK293T cells with linear fully deacylated polyethylenimine. J. Virol. Methods 146, 298-304. (Pubitemid 350030948)
12. \+ cells in patients undergoing transplantation for AIDS-related lym-phoma. Sci. Transl. Med. 2, 36ra43.
13. Dull, T., Zufferey, R., Kelly, M., et al. (1998). A third-generation lentivirus vector with a conditional packaging system. J. Virol. 72, 8463-8471. (Pubitemid 28471781)
14. Dupre, L., Marangoni, F., Scaramuzza, S., et al. (2006). Efficacy of gene therapy for Wiskott-Aldrich syndrome using a WAS promoter/cDNA-containing lentiviral vector and nonlethal irradiation. Hum. Gene Ther. 17, 303-313.
15. Escarpe, P., Zayek, N., Chin, P., et al. (2003). Development of a sensitive assay for detection of replication-competent recom-binant lentivirus in large-scale HIV-based vector preparations. Mol. Ther. 8, 332-341. (Pubitemid 37062843)
16. Farson, D., Witt, R., McGuinness, R., et al. (2001). A new-generation stable inducible packaging cell line for lentiviral vectors. Hum. Gene Ther. 12, 981-997. (Pubitemid 32681861)
17. Follenzi, A., and Naldini, L. (2002). HIV-based vectors: Preparation and use. Methods Mol. Med. 69, 259-274.
18. Galy, A., Roncarolo, M.G., and Thrasher, A.J. (2008). Development of lentiviral gene therapy for Wiskott-Aldrich syndrome. Expert Opin. Biol. Ther. 8, 181-190. (Pubitemid 351233711)
19. Geraerts, M., Michiels, M., Baekelandt, V., et al. (2005). Upscaling of lentiviral vector production by tangential flow filtration. J. Gene Med. 7, 1299-1310. (Pubitemid 41555436)
20. Graham, F.L., Smiley, J., Russell, W.C., et al. (1977). Characteristics of a human cell line transformed by DNA from human adenovirus type 5. J. Gen. Virol. 36, 59-74.
21. \+ cells with HIV-1-derived lentiviral vectors. Mol. Ther. 2, 71-80.
22. Hacein-Bey-Abina, S., Le Deist, F., Carlier, F., et al. (2002). Sustained correction of X-linked severe combined immunode-ficiencyby ex vivo gene therapy. N. Engl. J.Med. 346, 1185-1193. (Pubitemid 34984579)
23. Ikeda, Y., Takeuchi, Y., Martin, F., et al. (2003). Continuous high-titer HIV-1 vector production. Nat. Biotechnol. 21, 569-572. (Pubitemid 36532025)
24. Klages, N., Zufferey, R., and Trono, D. (2000). A stable system for the high-titer production of multiply attenuated lentiviral vectors. Mol. Ther. 2, 170-176.
25. Kuroda, H., Kutner, R.H., Bazan, N.G., et al. (2009). Simplified lentivirus vector production in protein-free media using polyethylenimine- mediated transfection. J. Virol. Methods 157, 113-121.
26. Kutner, R.H., Zhang, X.Y., and Reiser, J. (2009). Production, concentration and titration of pseudotyped HIV-1-based len-tiviral vectors. Nat. Protoc. 4, 495-505.
27. Levasseur, D.N., Ryan, T.M., Pawlik, K.M., et al. (2003). Correction of a mouse model of sickle cell disease: lentiviral/ anti-sickling b-globin gene transduction of unmobilized, purified hematopoietic stem cells. Blood 102, 4312-4319. (Pubitemid 37494089)
28. Levine, B.L., Humeau, L.M., Boyer, J., et al. (2006). Gene transfer in humans using a conditionally replicating lentiviral vector. Proc. Natl. Acad. Sci. U.S.A. 103, 17372-17377. (Pubitemid 44788976)
29. Lu, X., Humeau, L., Slepushkin, V., et al. (2004). Safe two-plasmid production for the first clinical lentivirus vector that achieves >99% transduction in primary cells using a one-step protocol. J. Gene Med. 6, 963-973. (Pubitemid 40228111)
30. Mantovani, J., Charrier, S., Eckenberg, R., et al. (2009). Diverse ge-nomic integration of a lentiviral vector developed for the treatment of Wiskott-Aldrich syndrome. J. Gene Med. 11, 645-654.
31. Marangoni, F., Bosticardo, M., Charrier, S., et al. (2009). Evidence for long-term efficacy and safety of gene therapy for Wiskott-Al-drich syndrome in preclinical models. Mol. Ther. 17, 1073-1082.
32. Mitta, B., Rimann, M., and Fussenegger, M. (2005). Detailed design and comparative analysis of protocols for optimized production of high-performance HIV-1-derived lentiviral particles. Metab. Eng. 7, 426-436. (Pubitemid 41790471)
33. Miyoshi, H., Blomer, U., Takahashi, M., et al. (1998). Development of a self-inactivating lentivirus vector. J. Virol. 72, 8150-8157.
34. Naldini, L., Blomer, U., Gage, F.H., et al. (1996). Efficient transfer, integration, and sustained long-term expression of the trans-gene in adult rat brains injected with a lentiviral vector. Proc. Natl. Acad. Sci. U.S.A. 93, 11382-11388. (Pubitemid 26347130)
35. Ni, Y., Sun, S., Oparaocha, I., et al. (2005). Generation of a packaging cell line for prolonged large-scale production of high-titer HIV-1-based lentiviral vector. J. Gene Med. 7, 818-834. (Pubitemid 40872867)
36. Ochs, H.D., and Thrasher, A.J. (2006). The Wiskott-Aldrich syndrome. J. Allergy Clin. Immunol. 117, 725-738. (Pubitemid 44313817)
37. Przybylowski, M., Hakakha, A., Stefanski, J., et al. (2006). Production scale-up and validation of packaging cell clearance of clinical-grade retroviral vector stocks produced in cell factories. Gene Ther. 13, 95-100. (Pubitemid 41823856)
38. Reiser, J. (2000). Production and concentration of pseudotyped HIV-1-based gene transfer vectors. Gene Ther. 7, 910-913. (Pubitemid 30386654)
39. Schambach, A., and Baum, C. (2008). Clinical application of lentiviral vectors: concepts and practice. Curr. Gene Ther. 8, 474-482.
40. Scherr, M., and Eder, M. (2002). Gene transfer into hematopoi-etic stem cells using lentiviral vectors. Curr. Gene Ther. 2, 45-55.
41. Scherr, M., Battmer, K., Eder, M., et al. (2002). Efficient gene transfer into the CNS by lentiviral vectors purified by anion exchange chromatography. Gene Ther. 9, 1708-1714. (Pubitemid 36104615)
42. Schonely, K., Afable, C., Slepushkin, V., et al. (2003). QC release testing of an HIV-1 based lentiviral vector lot and transduced cellular product. Bioproc. J. 2, 39-47.
43. Segura, M.M., Kamen, A., and Garnier, A. (2006). Downstream processing of oncoretroviral and lentiviral gene therapy vectors. Biotechnol. Adv. 24, 321-337.
44. Segura, M.M., Garnier, A., Durocher, Y., et al. (2007). Production of lentiviral vectors by large-scale transient transfection of suspension cultures and affinity chromatography purification. Biotechnol. Bioeng. 98, 789-799. (Pubitemid 350032683)
45. Selvaggi, T.A., Walker, R.E., and Fleisher, T.A. (1997). Development of antibodies to fetal calf serum with arthus-like reactions in human immunodeficiency virus-infected patients given syngeneic lymphocyte infusions. Blood 89, 776-779. (Pubitemid 27121269)
46. Slepushkin, V., Chang, N., Cohen, R., et al. (2003). Large-scale purification of a lentiviral vector by size exclusion chroma-tography or Mustang Q ion exchange capsule. Bioproc. J. 2, 89-95.
47. Throm, R.E., Ouma, A.A., Zhou, S., et al. (2009). Efficient construction of producer cell lines for a SIN lentiviral vector for SCID-X1 gene therapy by concatemeric array transfection. Blood 113, 5104-5110.
48. Transfiguracion, J., Jaalouk, D.E., Ghani, K., et al. (2003). Size-exclusion chromatography purification of high-titer vesicular stomatitis virus G glycoprotein-pseudotyped retrovectors for cell and gene therapy applications. Hum. Gene Ther. 14, 1139-1153. (Pubitemid 36930404)
49. Tuschong, L., Soenen, S.L., Blaese, R.M., et al. (2002). Immune response to fetal calf serum by two adenosine deaminase-deficient patients after T cell gene therapy. Hum. Gene Ther. 13, 1605-1610. (Pubitemid 35034680)
50. Zanta-Boussif, M.A., Charrier, S., Brice-Ouzet, A., et al. (2009). Validation of a mutated PRE sequence allowing high and sustained transgene expression while abrogating WHV-X protein synthesis: Application to the gene therapy of WAS. Gene Ther. 16, 605-619.
51. Zufferey, R., Dull, T., Mandel, R.J., et al. (1998). Self-inactivating lentivirus vector for safe and efficient in vivo gene delivery. J. Virol. 72, 9873-9880. (Pubitemid 28520853)
52. Zychlinski, D., Schambach, A., Modlich, U., et al. (2008). Physiological promoters reduce the genotoxic risk of integrating gene vectors. Mol. Ther. 16, 718-725. (Pubitemid 351426173)